Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.

Hosseini M, Rezvani HR, Aroua N, Bosc C, Farge T, Saland E, Guyonnet-Dupérat V, Zaghdoudi S, Jarrou L, Larrue C, Sabatier M, Mouchel PL, Gotanègre M, Piechaczyk M, Bossis G, Récher C, Sarry JE.

Cancer Res. 2019 Oct 15;79(20):5191-5203. doi: 10.1158/0008-5472.CAN-19-0515. Epub 2019 Jul 29.

PMID:
31358527
2.

Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia.

Larrue C, Heydt Q, Saland E, Boutzen H, Kaoma T, Sarry JE, Joffre C, Récher C.

Oncogenesis. 2019 Jul 16;8(8):39. doi: 10.1038/s41389-019-0148-9.

3.

Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia.

Stuani L, Riols F, Millard P, Sabatier M, Batut A, Saland E, Viars F, Tonini L, Zaghdoudi S, Linares LK, Portais JC, Sarry JE, Bertrand-Michel J.

Int J Mol Sci. 2018 Oct 25;19(11). pii: E3325. doi: 10.3390/ijms19113325.

4.

Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.

Bertoli S, Paubelle E, Bérard E, Saland E, Thomas X, Tavitian S, Larcher MV, Vergez F, Delabesse E, Sarry A, Huguet F, Larrue C, Bosc C, Farge T, Sarry JE, Michallet M, Récher C.

Eur J Haematol. 2019 Feb;102(2):131-142. doi: 10.1111/ejh.13183. Epub 2018 Nov 28.

PMID:
30325535
5.

Dexamethasone in hyperleukocytic acute myeloid leukemia.

Bertoli S, Picard M, Bérard E, Griessinger E, Larrue C, Mouchel PL, Vergez F, Tavitian S, Yon E, Ruiz J, Delabesse E, Luquet I, Linares LK, Saland E, Carroll M, Danet-Desnoyers G, Sarry A, Huguet F, Sarry JE, Récher C.

Haematologica. 2018 Jun;103(6):988-998. doi: 10.3324/haematol.2017.184267. Epub 2018 Mar 8.

6.

Dendrogenin A drives LXR to trigger lethal autophagy in cancers.

Segala G, David M, de Medina P, Poirot MC, Serhan N, Vergez F, Mougel A, Saland E, Carayon K, Leignadier J, Caron N, Voisin M, Cherier J, Ligat L, Lopez F, Noguer E, Rives A, Payré B, Saati TA, Lamaziere A, Despres G, Lobaccaro JM, Baron S, Demur C, de Toni F, Larrue C, Boutzen H, Thomas F, Sarry JE, Tosolini M, Picard D, Record M, Récher C, Poirot M, Silvente-Poirot S.

Nat Commun. 2017 Dec 4;8(1):1903. doi: 10.1038/s41467-017-01948-9.

7.

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.

Heydt Q, Larrue C, Saland E, Bertoli S, Sarry JE, Besson A, Manenti S, Joffre C, Mansat-De Mas V.

Oncogene. 2018 Feb 8;37(6):787-797. doi: 10.1038/onc.2017.376. Epub 2017 Oct 23.

8.

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J.

Leukemia. 2018 Mar;32(3):597-605. doi: 10.1038/leu.2017.284. Epub 2017 Sep 15.

PMID:
28914261
9.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, Récher C, Sarry JE.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.

10.

Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia.

Cerella C, Gaigneaux A, Mazumder A, Lee JY, Saland E, Radogna F, Farge T, Vergez F, Récher C, Sarry JE, Kim KW, Shin HY, Dicato M, Diederich M.

Leukemia. 2017 Mar;31(3):755-759. doi: 10.1038/leu.2016.341. Epub 2016 Nov 22. No abstract available.

11.

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy.

Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, Saland E, Castellano R, Pouyet L, Collette Y, Vey N, Chabannon C, Recher C, Sarry JE, Alcor D, Peyron JF, Griessinger E.

Blood. 2016 Jul 14;128(2):253-64. doi: 10.1182/blood-2015-07-655860. Epub 2016 Jun 2.

PMID:
27257182
12.

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.

Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, Sarry JE.

J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7.

13.

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.

Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S.

Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706.

14.

Knockout of Vdac1 activates hypoxia-inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation.

Brahimi-Horn MC, Giuliano S, Saland E, Lacas-Gervais S, Sheiko T, Pelletier J, Bourget I, Bost F, Féral C, Boulter E, Tauc M, Ivan M, Garmy-Susini B, Popa A, Mari B, Sarry JE, Craigen WJ, Pouysségur J, Mazure NM.

Cancer Metab. 2015 Aug 26;3:8. doi: 10.1186/s40170-015-0133-5. eCollection 2015.

15.

Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.

Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, Hospital MA, Tamburini J, Delabesse E, Manenti S, Sarry JE, Récher C.

Blood. 2016 Feb 18;127(7):882-92. doi: 10.1182/blood-2015-05-646497. Epub 2015 Aug 18.

PMID:
26286850
16.

Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.

Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.

Mol Cancer Ther. 2015 Oct;14(10):2364-73. doi: 10.1158/1535-7163.MCT-15-0163. Epub 2015 Jul 23.

17.

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17.

18.

Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.

Sesen J, Dahan P, Scotland SJ, Saland E, Dang VT, Lemarié A, Tyler BM, Brem H, Toulas C, Cohen-Jonathan Moyal E, Sarry JE, Skuli N.

PLoS One. 2015 Apr 13;10(4):e0123721. doi: 10.1371/journal.pone.0123721. eCollection 2015.

19.

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.

Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, de Toni F, Scotland S, David M, Danet-Desnoyers G, Vergez F, Barreira Y, Collette Y, Récher C, Sarry JE.

Blood Cancer J. 2015 Mar 20;5:e297. doi: 10.1038/bcj.2015.19.

20.

TOM1 is a PI5P effector involved in the regulation of endosomal maturation.

Boal F, Mansour R, Gayral M, Saland E, Chicanne G, Xuereb JM, Marcellin M, Burlet-Schiltz O, Sansonetti PJ, Payrastre B, Tronchère H.

J Cell Sci. 2015 Feb 15;128(4):815-27. doi: 10.1242/jcs.166314. Epub 2015 Jan 14.

21.

The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs.

Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, Pelegrin M, Kaoma T, Vallar L, Récher C, Manenti S, Piechaczyk M.

Cell Rep. 2014 Jun 26;7(6):1815-23. doi: 10.1016/j.celrep.2014.05.016. Epub 2014 Jun 5.

22.

Arabinogalactan protein 31 (AGP31), a putative network-forming protein in Arabidopsis thaliana cell walls?

Hijazi M, Roujol D, Nguyen-Kim H, Del Rocio Cisneros Castillo L, Saland E, Jamet E, Albenne C.

Ann Bot. 2014 Oct;114(6):1087-97. doi: 10.1093/aob/mcu038. Epub 2014 Mar 30.

23.

Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells.

Scotland S, Saland E, Skuli N, de Toni F, Boutzen H, Micklow E, Sénégas I, Peyraud R, Peyriga L, Théodoro F, Dumon E, Martineau Y, Danet-Desnoyers G, Bono F, Rocher C, Levade T, Manenti S, Junot C, Portais JC, Alet N, Récher C, Selak MA, Carroll M, Sarry JE.

Leukemia. 2013 Nov;27(11):2129-38. doi: 10.1038/leu.2013.107. Epub 2013 Apr 9.

PMID:
23568147
24.

The nucleophosmin-anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness.

Dupuis-Coronas S, Lagarrigue F, Ramel D, Chicanne G, Saland E, Gaits-Iacovoni F, Payrastre B, Tronchère H.

J Biol Chem. 2011 Sep 16;286(37):32105-14. doi: 10.1074/jbc.M111.227512. Epub 2011 Jul 7.

Supplemental Content

Loading ...
Support Center